Searched for
CADILA SHARE PRICE
For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Sell Cadila Healthcare, target price Rs 377: ICICI DirectCadila Healthcare Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 40816.62 Crore) operating in Pharm...
- Cadila Healthcare Q3 Results: Firm posts 5% decline in profit at Rs 500 crConsolidated total revenue from operations stood at Rs 3,655 crore during the quarter under review as compared to Rs 3,633 crore in the yea...
- Market Movers: What sparked gains in Vedanta and losses in Cadila?The brokerage, in particular, was bullish about Vedanta’s prospects as it upgraded the stock to “overweight” and raised its price target by...
- Will three-dose Covid vaccine give Cadila Healthcare a booster shot?Analysts do see a lift to its sales, even as some of them are not factoring in sales beyond FY23 amid uncertainty over booster shots. The p...
- Cadila Healthcare gains 2% on USFDA nod for Empagliflozin tabletsThe drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
- Buy Cadila Healthcare, target price Rs 330: CLSAThe brokerage said HCQS could be a huge near-term opportunity for Cadila.
- Buy Cadila Healthcare, target Rs 315: Nirmal Bang SecuritiesCadila Healthcare is a largecap company, operating in pharmaceuticals and health care sector.
- Add Cadila Healthcare, target Rs 292: ICICI SecuritiesCadila Healthcare is a largecap company, operating in pharmaceuticals and health care sector.
- Cadila Healthcare gains on USFDA nod for memory loss drugThe group now has 252 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
- Cadila share slips 5% after deal with HeinzZydus Wellness had on Wednesday said it will acquire Heinz India.
- Sell Cadila Healthcare, target Rs 345: Dr CK NarayanSell Cadila Healthcare Ltd. at a price target of Rs 345.0 and a stoploss at Rs 362 from entry point.
- Cadila up 2% as Gujarat plant gets no USFDA observationThe company had recently reported 53.26 per cent jump in consolidated net profit at Rs 590.8 crore.
- Cadila Healthcare rises 2% on USFDA approval to antibiotic drugThis medication is also used for prophylaxis of malaria.
- Buy Cadila Healthcare, target Rs 489: Anand RathiBuy Cadila Healthcare Ltd. at a price target of Rs 489.0 .
- Buy Cadila Healthcare, target Rs 460: Motilal OswalBuy Cadila Healthcare, at a price target of Rs 460.
- Buy Cadila Healthcare, target Rs 415: Sagar DoshiBuy Cadila Healthcare Ltd. at a price target of Rs 415.0 and a stop loss at Rs 380 from entry point.
- Buy Cadila Healthcare, target Rs 444: Equirus SecuritiesBuy Cadila Healthcare Ltd. at a price target of Rs 444.0 .
- Cadila Healthcare soars over 4% post USFDA drug nodCLSA has upgraded Cadila Healthcare to ‘buy’ from ‘underperform’.
Load More
